Healthcare
Live Price
Offline$0.1295
+24.64% today
Window Change
+355.99%
Window
Jun 23, 2025 โ May 15, 2026
Coverage: 225 bars ยท Jun 23, 2025 โ May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bristol-Myers Squibb Company Ce (CELG-RI) is a Healthcare stock with a market cap of $264.45M. The stock last traded around $0.13 and up 356.0% across the available one-year price window (Jun 23, 2025 โ May 15, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +178.7%, a dividend yield of 0.0%. What stands out right now is revenue -0.2%, EPS +178.7%, free cash flow -7.9% with operating margin 34.0% and ROIC 13.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CELG-RI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.2% vs +7.6% peer median
Operating Margin
Above sector median
+34.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.2% and EPS is at +178.7%, with operating margin around 34.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +12.4% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +9.1% | +37.0% | โ |
2026 Feb 5, 2026 | +2.4% | -1.9% | +7.8% | +30.9% |
2025 Oct 30, 2025 | -28.9% | +0.0% | -7.7% | -12.5% |
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CELG-RI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
CELG-RI Max Drawdown
-64.27%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CELG-RI and SPY.
Company Overview
Bristol-Myers Squibb Company Ce
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.